Menu Back toGCP Quality and Compliance: The Regulator’s Perspective

DIA 2021 Global Annual Meeting

GCP Quality and Compliance: The Regulator’s Perspective

Session Chair(s)

David  Fryrear, MS

David Fryrear, MS

  • Executive Vice President and Head of Quality Assurance
  • Astellas, United States
In this forum, leaders from regulatory authorities will present trends they are seeing in inspections, discuss emerging compliance challenges, and answer questions on expected practices that support success in quality in clinical development.
Learning Objective : Discuss trends observed in recent inspections and understand specific areas of interest of regulatory authorities; Describe how quality management systems and risk-based approaches need to evolve to address emerging challenges; Recognize regulatory expectations.


David C. Burrow, JD, PharmD


David C. Burrow, JD, PharmD

  • Director, Office of Scientific Investigations, OC, CDER
  • FDA, United States
Hocine  Abid, MD, MBA


Hocine Abid, MD, MBA

  • National Manager, Regulatory Operations and Enforcement Branch
  • Health Canada, Canada
Paula  Walker, MA


Paula Walker, MA

  • Head of Compliance (GCP, GPvP, GLP & GxP Expert Circle)
  • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom